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Abstract
Objective—To determine whether, among women with gestational diabetes (GDM), gestational 
weight gain above Institute of Medicine (IOM) guidelines increases the risk of large for 
gestational age (LGA) neonates.
Study Design—We conducted a retrospective cohort study of singleton term pregnancies with 
GDM delivered at University of North Carolina Women’s Hospital, Chapel Hill, NC from January 
2002 to May 2010. We used Poisson regression modeling to estimate LGA risk (birth weight > 
90th percentile for gestational age), by body mass index class and adherence to 2009 IOM weight 
gain guidelines. Women meeting IOM guidelines were the referent group. Final adjusted models 
included race/ethnicity, medical management of GDM, and gestational age at delivery.
Results—Among the 466 women studied, mean ± standard deviation birth weight was 3,526 ± 
544 g; 18% (82/466) delivered LGA neonates. Birth weight was greatest among women 
exceeding, compared with meeting or gaining less than, IOM guidelines (3,703 ± 545 vs. 3,490 ± 
505 vs. 3,328 ± 503, p = 0.001). Exceeding IOM guideline was associated with LGA among obese 
women (adjusted risk ratio 2.62, 95% confidence interval 1.25, 5.50) but not among overweight or 
normal weight women.
Conclusion—Targeting gestational weight gain, a modifiable risk factor, independent of GDM 
treatment, may decrease LGA risk. Women with GDM may benefit from tailored weight gain 
recommendations.
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Women with gestational diabetes (GDM) are at an increased risk of large for gestational age 
(LGA) neonates due to hyperglycemia-mediated in utero fetal overgrowth.1 LGA, defined as 
birth weight > 90th percentile for gestational age, is associated with short- and long-term 
adverse outcomes, and these risks may be further compounded by maternal prepregnancy 
weight and weight gain, each of which is an independent risk factor for fetal overgrowth.2–4 
Such fetal overgrowth increases the risk of shoulder dystocia and birth injury among women 
witha vaginal birth and increases the risk of both primary cesarean birth and unsuccessful 
trial of labor after a cesarean delivery.5,6 For the neonate, in utero overgrowth and LGA at 
birth are associated with increased risks of neonatal hypoglycemia as well as overweight, 
obesity, and glucose intolerance in later life.7
In 2009, the Institute of Medicine (IOM) replaced the former 1990 gestational weight gain 
guidelines.8,9 Under the new guidelines, recommended gestational weight gain remains 
specific to prepregnancy body mass index (BMI).8,9 More women are classified as above-
normal weight, and recommended weight gain for obese women was lowered from “at least 
15 lb” to “11 to 20 lb.”9 These guidelines aim to optimize maternal and infant outcomes in a 
low-risk population. It is not known whether adherence to these guidelines is equally 
applicable for women with the increasingly prevalent complication of GDM. A positive 
association between early excessive weight gain and later GDM3,10,11 as well as infant birth 
weight12–14 has been reported. However, GDM is not routinely diagnosed until the third 
trimester, and guidelines for a non-GDM population may no longer be appropriate for those 
women.
Management strategies to achieve optimal glycemic control and thereby decrease the risk of 
adverse outcomes exist for women with GDM. However, whether adherence to gestational 
weight gain guidelines is also associated with improved outcome is not known. In the 
current analysis, we sought to determine whether gestational weight gain above IOM weight 
gain guidelines increases the risk of LGA neonates among women with GDM.
Material and Methods
We performed a retrospective cohort study of women with singleton pregnancies who were 
diagnosed with GDM and had a term delivery at University of North Carolina Women’s 
Hospital (UNC), Chapel Hill, NC from January 1, 2002 to May 31, 2010. Multiple 
gestations, preterm birth < 37 0/7 weeks, women with pre-gestational diabetes mellitus and 
those without documented GDM screening and diagnostic test results were excluded. 
University of North Carolina Institutional Review Board approval was obtained for this 
study.
During the study period, GDM was diagnosed using a two-step process. Universal screening 
with a 50 g, 1-hour oral glucose load was performed between 24 and 28 weeks’ gestation, 
with plasma glucose 2: 140 mg/dL considered screen positive. Diagnostic testing included a 
100 g, 3-hour oral glucose tolerance test (OGTT). Women meeting National Diabetes Group 
(NDDG) criteria15 were diagnosed with GDM and received nutritional counseling and 
instruction for glucose self-monitoring. Only women whose GDM screening followed this 
standard protocol were captured for this analysis. During the study period, the clinical 
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protocol at our institution defined adequate glycemic control as 50% or more of blood 
glucose levels at goal levels (fasting < 105 mg/dL and 1-hour postprandial < 140 mg/dL or 
2-hour postprandial < 130 mg/dL). Medical therapy was initiated (subcutaneous insulin or 
oral glyburide) or escalated if adequate glycemic control was not achieved, as determined by 
the primary obstetrical provider.
Data for this analysis were obtained from the UNC perinatal database (PD) and direct chart 
abstraction. The UNC PD is maintained by trained abstractors who enter information for 
each birth at UNC, abstracting data from the prenatal and intrapartum clinical record. Use of 
the UNC PD for research purposes has been described elsewhere.16 We obtained maternal 
demographic and pregnancy data from the PD, including self-reported race/ethnicity 
(choices in prenatal record were Caucasian, African American, Hispanic, Asian, or specify 
other). Gestational age was established by last menstrual period, if reliable, or by earliest 
ultrasound. Data abstractors entered the “final estimated due date” as recorded by the 
primary obstetric provider. Measured or self-reported height, prepregnancy self-reported 
weight, initial prenatal visit measured weight, and final prenatal visit measured weight was 
abstracted directly from the prenatal record.
Our primary study outcome was birth of a LGA neonate defined as gestational-age–specific 
birth weight above the 90th percentile, according to Oken et al.17 BMI (kg/m2) and 
gestational weight gain were calculated and classified as follows. BMI was calculated using 
height and self-reported prepregnancy weight, available for 75% of women. If pre-
pregnancy weight was not available, measured first prenatal visit weight < 20 weeks was 
used. For the about 25% of women for whom we abstracted first prenatal visit weight, the 
median gestational age was less than 12 weeks, and BMI was similar between women with 
self-reported weight and first visit weight. Gestational weight gain was calculated by 
subtracting weight used for BMI calculation from weight at last prenatal visit 2: 35 weeks 
and within 2 weeks of delivery. All women with a term delivery had a prenatal care visit 
with weight recorded within 2 weeks of delivery.
We characterized our cohort by adherence to BMI-specific 2009 IOM gestational weight 
gain guidelines.9 Women who lost weight were classified as gaining less than IOM 
guidelines and included 1 normal weight woman, 1 overweight woman, and 19 obese 
women. We compared characteristics and laboratory data among women who gained less 
than, within, or more than the 2009 IOM guidelines. We compared proportion of women 
who adhered to 2009 IOM guidelines by BMI class (normal, overweight, and obese). These 
bivariate analyses were performed with one way ANOVA test for normally distributed 
continuous and Pearson chi-square for categorical variables. Pairwise comparisons were 
performed with Student t-test.
For all other analyses, we a priori classified women by BMI class as normal weight, 
overweight, and obese. Analyses were performed separately for each BMI class. We 
excluded the 1% (6/472) of women who were underweight from all analyses. Women who 
gained within IOM guidelines were the reference group. We estimated unadjusted and 
adjusted risk ratios (RR, aRR) with 95% confidence intervals (95% CI) for LGA using 
Poisson regression modeling, allowing for nonconvergence of statistical models. Covariates 
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considered for inclusion in models included maternal demographics and laboratory data that 
differed by adherence to IOM guidelines. Covariates were considered significant if 
excluding them changed the effect estimate by > 10% or if they were independently 
associated with the outcome. Fasting blood glucose of the OGTT, while significant in 
bivariate analysis, did not impact magnitude of aRRs, significance, or precision of 
confidence intervals and was not forced into adjusted models. Final aRRs included race/
ethnicity and need for medical management of GDM (dichotomized as diet-control vs. any 
pharmacologic treatment that included insulin and/or glyburide), which remained significant 
in the model, and gestational age at delivery, which the authors chose to force into the 
model.
Results
Over the 8-year study period, 37,767 women delivered at UNC Women’s Hospital, 29,544 
had complete GDM screening results that followed the institution’s standard algorithm and 
2.4% (699/29,544) were diagnosed with GDM. Of these, 78.4% (548/699) had term, 
singleton deliveries. Complete prepregnancy BMI and weight gain data were available for 
86% (472/548), and the final cohort for analysis included 466 women after exclusion of the 
6 underweight women. Women missing complete BMI and weight gain data, compared with 
the 466 included in analysis, were of similar maternal age at delivery, ethnicity, and 
gestational age at term delivery. Among these 466 women, prepregnancy BMI data were 
used for 75% (349/466), and early pregnancy BMI data were used for 25% (117/466). Study 
fiow chart is shown in Fig. 1. Demographic data are shown in Table 1 with bivariate 
analysis by adherence to IOM weight gain guidelines.
By baseline BMI, 24% (110/466), 36% (167/466), and 41% (189/466) of women were 
normal weight, overweight, and obese, respectively. Among three prepregnancy BMI 
classes absolute maternal weight gain differed (p = 0.01). In pairwise comparisons, mean ± 
standard deviation (SD) weight gain among normal weight women was 27 ± 15.6 lb, similar 
to mean weight gain among overweight women (25 ± 20.1 lb; p = 0.4) but significantly 
more than obese women (20 ± 18.5 lb; p = 0.002). Gestational weight gain was also 
significantly different between overweight and obese women in pairwise comparisons (p = 
0.02).
Adherence to IOM weight gain guidelines also differed by prepregnancy BMI class as 
shown in Table 2 (overall p = 0.001). Normal weight women were most likely to gain less 
than IOM guidelines, compared with either overweight (45 vs. 28%, p = 0.002) or obese 
women (45 vs. 28%, p = 0.003). Obese women were more likely to gain more than IOM 
guidelines, compared with normal weight women (49 vs. 29%, p < 0.001). Other pairwise 
comparisons were not significant.
Mean ± SD birth weight was 3,526 ± 544 g and was greatest among obese women, 
compared with overweight or normal weight women (3,703 ± 545 vs. 3,490 ± 505 vs. 3,328 
± 503 g, p < 0.001). A total of 18% (82/466) of women delivered a LGA neonate. Obese 
women delivered significantly more LGA neonates (49/189, 26%) than either overweight 
(24/167, 14%) or normal weight (9/110, 8%) women (p < 0.001). Using the women in each 
Berggren et al. Page 4
Am J Perinatol. Author manuscript; available in PMC 2016 January 05.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
prepregnancy BMI class who met IOM weight gain guidelines as the reference group, we 
examined LGA risk by weight gain that was less than or exceeded IOM guidelines. These 
data are presented in Table 3. Exceeding IOM guidelines was associated with LGA in obese 
women in unadjusted (RR 2.44, 95% CI 1.18, 5.04) and adjusted analyses (aRR 2.62, 95% 
CI 1.25, 5.50) that included race/ethnicity, medical management of GDM, and gestational 
age at delivery. Among overweight and normal weight women, exceeding IOM guidelines 
was not associated with risk of LGA in unadjusted or adjusted analyses.
Discussion
Among a cohort of women diagnosed with GDM, obese women gained the least amount of 
weight during pregnancy but were more likely than normal weight women to exceed BMI-
specific recommended weight gain guidelines. Nearly one in five neonates was LGA, with 
the greatest proportion among obese women. Exceeding recommended weight gain was 
associated with LGA among obese women with GDM, regardless of need for medical 
treatment. An increased LGA risk was also observed among overweight women but this was 
not statistically significant, perhaps due to a smaller number of women in this BMI class. 
These findings suggest weight gain in excess of IOM guidelines modifies LGA risk among 
obese women with GDM.
Our analysis, specific to women already diagnosed with GDM, is unique among others 
examining prepregnancy BMI, gestational weight gain, and adverse outcome risk. Several 
studies have demonstrated an association between early excessive weight gain and 
subsequent GDM or glucose intolerance.10,11,18,19 Maternal prepregnancy BMI has also 
been positively associated with GDM, independent of early weight gain,20 and excessive 
weight gain is independently associated with infant birth weight.12–14 These findings have 
prompted suggestions for preconception and early pregnancy counseling regarding maternal 
weight gain.
Focusing on women with GDM, who are typically already in the third trimester of 
pregnancy, has important clinical applications. Ouzounian et al reported excessive weight 
gain was associated with macrosomia, defined as birth weight > 4,000 g for their analysis, 
risk among women with diet-controlled GDM.21 While we report LGA instead of a precise 
birth weight, study comparisons are valid, as LGA and neonates > 4,000 g were almost 
identical in our cohort; only seven LGA neonates were not also > 4,000 g. Similar to our 
findings, while weight gain was lowest among obese women, they were most likely to 
exceed recommendations.21 However, while Ouzounian et al found an increased risk among 
all BMI classes and the greatest risk among overweight women, our findings were only 
significant among obese women. These differences may refiect cohort differences, as 
Ouzounian et al evaluated only diet-controlled gestational diabetics, a large proportion of 
Asian women, and an about 12% prevalence of macrosomia.21 Horosz et al evaluated a 
GDM cohort by adherence to IOM guidelines and reported an association between excessive 
GWG through time of third trimester diagnosis and LGA neonates among overweight and 
obese women, but their association was no longer significant when total GWG was 
considered.22 Treatment may have attenuated this relationship, and may explain differences 
in our findings.
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Our cohort may represent women at higher baseline risk and with poorer glycemic control 
where gestational weight gain was not as substantial a factor in LGA risk. Nonetheless, our 
data suggest, among women with GDM, weight gain in excess of current guidelines may 
increase risk of neonatal LGA. Whether women with GDM may still benefit from third 
trimester interventions to decrease gestational weight gain is unknown. Women with GDM 
may be ideal candidates for interventions to slow their weight gain trajectory. Small trials in 
European cohorts have already suggested weight gain may be modified in obese 
women.23,24
Strengths of our study include a large sample size of women with GDM at a single 
institution. Clinical care guidelines were consistent during the 8 years included in our 
analysis. In addition, a single author abstracted weight data directly from the patient medical 
record. Limitations of this study include its retrospective design. Height and prepregnancy 
weight was self-reported, and weight may be under-reported. However, as routine clinical 
practice typically collects prepregnancy weight data by patient self-report, our research 
results may still be generalizable.
By including only term births, we may have excluded women whose preterm births were 
associated with either too little or too much weight gain. Excluding 15% of women 
otherwise meeting study inclusion criteria but without data to calculate BMI and weight gain 
likely did not impact results, as these women did not differ on other abstracted variables 
from those included. We did not differentiate weight gain before versus after GDM 
diagnosis. Thus, we do not know from our data whether the driving factor for LGA is weight 
gain before diagnosis, after initiation of GDM treatment, or a combination of both. 
Importantly, while exceeding recommended weight gain was not significantly associated 
with LGA among overweight women, this may be primarily due to our smaller sample of 
overweight women. Among normal weight women, the number of LGA infants was too 
small to provide meaningful information. Despite limitations, our data offer important 
insight for third trimester counseling and care of women with GDM, especially those who 
enter pregnancy obese and who are on a trajectory to exceed current guidelines for weight 
gain in pregnancy.
Up to 30% of women enter pregnancy obese, and even more are overweight.25 GDM 
prevalence has also risen in parallel with the increasing obesity epidemic.26 These factors, 
along with gestational weight gain, each contribute to infant birth weight. Current 2009 IOM 
guidelines for weight gain in pregnancy have classified more women as above normal BMI 
and lowered weight gain recommendations for obese women. Concern for small for 
gestational age (SGA) infants with too little weight gain among obese women has appeared 
to be of little concern,9 until a recent publication by Catalano et al readdressed this outcome 
and showed obese, as well as overweight, women gaining under 5 kg had increased SGA 
risk.27 These findings, as well as other neonatal anthropometrics, held true when diabetic 
status was considered.27 Whether current guidelines optimize neonatal outcomes without 
increasing risks and whether tailored guidelines may benefit women following a GDM 
diagnosis remains uncertain. Nonetheless, it remains an essential question to tackle for such 
a prevalent outcome as LGA, as close to one in five had an LGA infant in our cohort.
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For women who enter pregnancy overweight or obese and are diagnosed with GDM, 
addressing gestational weight gain, in conjunction with current standard-of-care glycemic 
control efforts, may improve outcomes. Further, earlier screening and diagnosis of GDM 
may allow more time to implement tailored weight gain recommendations. Further studies 
should identify optimal weight gain for women with GDM. Interventions should be patient-
centered, evaluate innovative ways of engaging patients to follow our evidence-based 
recommendations, and assess whether achieving recommended weight gain can modify risk 
of an LGA neonate and reduce the long-term consequences of maternal overweight and 
glucose intolerance for child health.
References
1. Langer O, Yogev Y, Most O, Xenakis EM. Gestational diabetes: the consequences of not treating. 
Am J Obstet Gynecol. 2005; 192(4):989–997. [PubMed: 15846171] 
2. Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the Fifth 
International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care. 2007; 
30(Suppl 2):S251–S260. [PubMed: 17596481] 
3. Hedderson MM, Weiss NS, Sacks DA, et al. Pregnancy weight gain and risk of neonatal 
complications: macrosomia, hypoglycemia, and hyperbilirubinemia. Obstet Gynecol. 2006; 108(5):
1153–1161. [PubMed: 17077237] 
4. Heude B, Thiébaugeorges O, Goua V, et al. EDEN Mother-Child Cohort Study Group. Pre-
pregnancy body mass index and weight gain during pregnancy: relations with gestational diabetes 
and hypertension, and birth outcomes. Matern Child Health J. 2012; 16(2):355–363. [PubMed: 
21258962] 
5. Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. 
Diabetes Care. 2007; 30(Suppl 2):S141–S146. [PubMed: 17596462] 
6. Chauhan SP, Grobman WA, Gherman RA, et al. Suspicion and treatment of the macrosomic fetus: a 
review. Am J Obstet Gynecol. 2005; 193(2):332–346. [PubMed: 16098852] 
7. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth 
weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005; 115(3):e290–e296. 
[PubMed: 15741354] 
8. Institute of Medicine. Nutrition during Pregnancy: Part I, Weight Gain; Part II, Nutrient 
Supplements. National Academy Press; Washington, DC: 1990. (Subcommittees on Nutritional 
Status and Weight Gain during Pregnancy and Dietary Intake and Nutrient Supplements During 
Pregnancy, Committee on Nutritional Status During Pregnancy and Lactation, Food and Nutrition 
Board). 
9. Institute of Medicine. Weight Gain during Pregnancy: Reexamining the Guidelines. National 
Academy Press; Washington, DC: 2009. (Committee to Reexamine IOM Pregnancy Weight 
Guidelines, Food and Nutrition Board and Board on Children, Youth, and Families.). 
10. Carreno CA, Clifton RG, Hauth JC, et al. Eunice Kennedy Shriver National Institute of Child 
Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. 
Excessive early gestational weight gain and risk of gestational diabetes mellitus in nulliparous 
women. Obstet Gynecol. 2012; 119(6):1227–1233. [PubMed: 22617588] 
11. Gibson KS, Waters TP, Catalano PM. Maternal weight gain in women who develop gestational 
diabetes mellitus. Obstet Gynecol. 2012; 119(3):560–565. [PubMed: 22353954] 
12. Ferraro ZM, Barrowman N, Prud’homme D, et al. Excessive gestational weight gain predicts large 
for gestational age neonates independent of maternal body mass index. J Matern Fetal Neonatal 
Med. 2012; 25(5):538–542. [PubMed: 22081936] 
13. Simas TA, Waring ME, Liao X, et al. Prepregnancy weight, gestational weight gain, and risk of 
growth affected neonates. J Womens Health (Larchmt). 2012; 21(4):410–417. [PubMed: 
22165953] 
Berggren et al. Page 7
Am J Perinatol. Author manuscript; available in PMC 2016 January 05.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
14. Crane JM, White J, Murphy P, Burrage L, Hutchens D. The effect of gestational weight gain by 
body mass index on maternal and neonatal outcomes. J Obstet Gynaecol Can. 2009; 31(1):28–35. 
[PubMed: 19208280] 
15. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other 
categories of glucose intolerance. Diabetes. 1979; 28(12):1039–1057. [PubMed: 510803] 
16. Berggren EK, Boggess KA, Stuebe AM, Jonsson Funk M. National Diabetes Data Group vs 
Carpenter-Coustan criteria to diagnose gestational diabetes. Am J Obstet Gynecol. 2011; 
205(3):e1–e7. [PubMed: 22071053] 
17. Oken E, Kleinman KP, Rich-Edwards J, Gillman MW. A nearly continuous measure of birth 
weight for gestational age using a United States national reference. BMC Pediatr. 2003; 3:6. 
[PubMed: 12848901] 
18. Hedderson MM, Gunderson EP, Ferrara A. Gestational weight gain and risk of gestational diabetes 
mellitus. Obstet Gynecol. 2010; 115(3):597–604. [PubMed: 20177292] 
19. Herring SJ, Oken E, Rifas-Shiman SL, et al. Weight gain in pregnancy and risk of maternal 
hyperglycemia. Am J Obstet Gynecol. 2009; 201(1):e1–e7.
20. Torloni MR, Betrán AP, Horta BL, et al. Prepregnancy BMI and the risk of gestational diabetes: a 
systematic review of the literature with meta-analysis. Obes Rev. 2009; 10(2):194–203. [PubMed: 
19055539] 
21. Ouzounian JG, Hernandez GD, Korst LM, et al. Pre-pregnancy weight and excess weight gain are 
risk factors for macrosomia in women with gestational diabetes. J Perinatol. 2011; 31(11):717–
721. [PubMed: 21372797] 
22. Horosz E, Bomba-Opon DA, Szymanska M, Wielgos M. Maternal weight gain in women with 
gestational diabetes mellitus. J Perinat Med. 2013; 41(5):523–528. [PubMed: 23492551] 
23. Vinter CA, Jensen DM, Ovesen P, Beck-Nielsen H, Jørgensen JS. The LiP (Lifestyle in 
Pregnancy) study: a randomized controlled trial of lifestyle intervention in 360 obese pregnant 
women. Diabetes Care. 2011; 34(12):2502–2507. [PubMed: 21972411] 
24. Bogaerts AF, Devlieger R, Nuyts E, Witters I, Gyselaers W, Van den Bergh BR. Effects of 
lifestyle intervention in obese pregnant women on gestational weight gain and mental health: a 
randomized controlled trial. Int J Obes (Lond). 2013; 37(6):814–821. [PubMed: 23032404] 
25. Guelinckx I, Devlieger R, Beckers K, Vansant G. Maternal obesity: pregnancy complications, 
gestational weight gain and nutrition. Obes Rev. 2008; 9(2):140–150. [PubMed: 18221480] 
26. Langer O, Yogev Y, Xenakis EM, Brustman L. Overweight and obese in gestational diabetes: the 
impact on pregnancy outcome. Am J Obstet Gynecol. 2005; 192(6):1768–1776. [PubMed: 
15970805] 
27. Catalano PM, Mele L, Landon MB, et al. Eunice Kennedy Shriver National Institute of Child 
Health and Human Development Maternal-Fetal Medicine Units Network. Inadequate weight gain 
in overweight and obese pregnant women: what is the effect on fetal growth? Am J Obstet 
Gynecol. 2014
Berggren et al. Page 8
Am J Perinatol. Author manuscript; available in PMC 2016 January 05.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Fig. 1. 
Flow chart of the study.
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Table 1
Maternal demographic and laboratory data by adherence to 2009 IOM guidelines
< IOM recs
(n = 149)
= IOM recs
(n = 124)
> IOM recs
(n = 193)
Mean ± SD or n (%)
Maternal age at delivery (y) 32.0 ± 5.3 31.1 ± 5.5 30.5 ± 6.0
Ethnicity
a
Caucasian 38 (26) 28 (23) 51 (26)
African American 12 (8) 6 (5) 35 (18)
Hispanic 99 (66) 90 (73) 107 (55)
Gestational age at term delivery (wks) 39.1 ± 0.99 39.0 ± 0.97 39.2 ± 1.0
50 g 1-h oral glucose load 175 ± 27.4 174 ± 23.8 174 ± 23.3
100 g 3-h oral glucose tolerance test
Fasting
a 82 ± 17.2 97 ± 20.0 99 ± 15.6
1 h 207 ± 28.7 213 ± 30.2 211 ± 31.0
2 h 191 ± 35.1 191 ± 39.0 190 ± 34.3
3 h 146 ± 38.6 142 ± 43.0 138 ± 44.1
Pharmacologic management (insulin or oral medication) 69 (46) 67 (54) 115 (60)
Abbreviations: IOM, Institute of Medicine; SD, standard deviation.
a
p < 0.05.
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Table 2
Adherence to 2009 IOM guidelines by BMI class
Adherence to IOM guidelines
< IOM
a
(n = 149)
= IOM
(n = 124)
> IOM
(n = 193)
BMI class n (%)
Normal weight (n = 110) 50 (45) 28 (25) 32 (29)
Overweight (n = 167) 46 (28) 55 (32) 68 (41)
Obese (n = 189) 53 (28) 42 (23) 93 (49)
Abbreviations: BMI, body mass index; IOM, Institute of Medicine.
a
21 women (1 normal weight, 1 overweight, and 19 obese) lost weight and were classified as gaining < IOM guidelines; overall Pearson chi-
square, p = 0.001.
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Table 3
Risk of LGA by IOM guidelines in each BMI class
Birth Weight (g)
a LGA (n)/
sample (n)
< IOM guidelines
(149/466)
> IOM guidelines
(193/466)
RR (95% CI) aRR (95% CI) RR (95% CI) aRR (95% CI)
Normal 3,328 ± 503 9/110 0.28 (0.05, 1.44) 0.53 (0.10, 2.74) 0.66 (0.16, 2.70) 0.42 (0.13, 1.40)
Overweight 3,490 ± 505 24/167 0.96 (0.31, 2.95) 1.05 (0.68, 4.19) 1.69 (0.69, 4.16) 1.68 (0.68, 4.19)
Obese 3,703 ± 545 49/189 0.58 (0.20, 1.70) 0.62 (0.21, 1.84) 2.44 (1.18, 5.04) 2.62 (1.25, 5.50)
Abbreviations: aRR, adjusted risk ratio; BMI, body mass index; IOM, Institute of Medicine; LGA, large for gestational age; RR, unadjusted risk 
ratio.
Notes: Reference group, IOM weight gain guidelines met (124/466).
Normal (BMI 18.5–24.9), overweight (BMI 25.0–29.9), obese (BMI > 30.0); final models adjusted for race/ethnicity, medical management of 
GDM, and gestational age at delivery.
a
p < 0.001 for birth weight different by BMI class.
Am J Perinatol. Author manuscript; available in PMC 2016 January 05.
